Dr. Armstrong Discusses Hereditary Prostate Cancer

Andrew J. Armstrong, MD
Published: Wednesday, Nov 01, 2017



Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

One of the most important findings of the past year was the identification of a form of hereditary prostate cancer, Armstrong says.

These mutations are called homologous repair enzymes, which create a very aggressive form of prostate cancer that effects 10% to 15% of men with metastatic prostate cancer.
 
SELECTED
LANGUAGE


Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

One of the most important findings of the past year was the identification of a form of hereditary prostate cancer, Armstrong says.

These mutations are called homologous repair enzymes, which create a very aggressive form of prostate cancer that effects 10% to 15% of men with metastatic prostate cancer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x